Background Ambulatory blood pressure monitoring (ABPM) has been proposed as a useful tool for more accurately diagnosing hypertension (HTN) and evaluating blood pressure (BP) response in pediatric anti-hypertensive trials. ABPM captures multiple BP measurements during routine daily activities and is thus an excellent method for identifying white-coat HTN. Additionally, ABPM measurements in adults do not demonstrate the placebo effect commonly seen with casual BP measurements, although this has yet to be evaluated in children. Therefore,, the aim of this study was to assess the effect of placebo on ABPM measurements in children. Methods A total of 141 children aged 5-16 years with elevated BP were randomized into a multi-center, singleblind, cross-over trial. Subjects received a placebo pill prior to wearing a 24-h ABPM device at one of two visits separated by 1-2 weeks. Study procedures were otherwise identical at both visits. Results Mean systolic and diastolic BP for all measured time periods were similar between visits, as was the number of children diagnosed with HTN at each visit. Conclusion Having confirmed HTN at baseline did not affect the impact of placebo on mean BP. If confirmed, this lack of placebo effect on ABPM measurements may allow for the design of direct comparison pediatric antihypertensive trials without a placebo arm.
Introduction
Hypertension (HTN) affects 3-5 % of children and adolescents [1] [2] [3] [4] [5] [6] [7] . Since the enactment of the Food and Drug Administration (FDA) Modernization Act in 1997, a number of clinical trials have evaluated the safety and efficacy of various anti-hypertensive medications in these children. Of the different study designs endorsed by the FDA to study drug efficacy of anti-hypertensive medications in children, all but one contain some component of placebo comparison [8] . While the use of placebo for the short duration of these trials has been shown to be safe [8] , the long-term impact of delaying therapy in hypertensive children is unknown. Thus, children with indications for immediate pharmacologic therapy are typically excluded from these studies [9] .
The traditional primary outcome measure for antihypertensive trials in children is the change in seated 24-hour "trough" auscultatory blood pressure (BP) measurements after repeated daily dosing. Unfortunately, "trough" BP measurements have several inherent limitations. Between 13 and 53 % of children have white-coat HTN [10] [11] [12] , a condition in which BP elevation is limited to clinical settings. The inclusion of these children in antihypertensive trials may negatively bias the results as these subjects were not truly hypertensive at baseline. Additionally, 24-h trough BP may miss an immediate BP lowering response of medications with time-limited effects. Finally, routine auscultatory BP measurements are highly subject to the placebo effect [13] , thus necessitating that a placebo arm be included in most efficacy trials.
Ambulatory BP monitoring (ABPM) has been proposed as an alternate way of assessing BP response in pediatric clinical trials. ABPM captures subjects' BP in a non-clinical setting multiple times over an extended time period, thus allowing one to identify subjects with sustained HTN (as opposed to white-coat HTN) accurately for inclusion in the study. ABPM also provides a method to evaluate the duration of effects of anti-hypertensive medications. Lastly, evaluating the mean of multiple BP readings obtained with ABPM devices provides a better indicator of the overall variability inherent in an individual's BP. Better quantification of this variability as mean BP may ultimately decrease the impact that placebo has on BP. The study reported here was thus designed to measure the effect of placebo on BP measured by ABPM in drug-naïve children with an elevated BP (≥90th percentile).
Methods
A multi-center randomized cross-over study was performed among five participating sites of the Network of Pediatric Pharmacology Research Units (National Institute of Child Health and Human Development). All study procedures were approved by the local Institutional Review Boards (IRB) of each institution. Written informed consent was obtained from a parent/legal guardian for all subjects. Subject assent was obtained when indicated by local IRB practices.
Study population
Children aged 5-16 years with a history of borderline or significant but not severe HTN who were not receiving antihypertensive medications were eligible for enrollment. Subjects underwent a screening examination with three auscultatory BP measurements using a calibrated aneroid manometer and appropriate sized cuff according to American Heart Association standards [14] . Those with a mean systolic BP (SBP) or diastolic BP (DBP) ≥90th percentile for age, height, and gender [15] , but >10 mmHg above the 99th percentile [16] per published guidelines at the time of screening were enrolled in the study. Additionally, subjects with significant dysrhythmias (which interfere with the ability of the ABPM devices to accurately measure BP) and those on medications which alter BP (e.g., corticosteroids or stimulants) whose dose had been changed within 4 weeks of study entry were excluded.
Study procedures
The subjects completed two study visits over a 2-week period. At each visit, subjects underwent six auscultatory BP measurements using a calibrated aneroid manometer followed by a 24-h ambulatory monitoring period utilizing the Space Labs 90217 oscillometric monitor (Issaquah, WA). At visit 1, eligible subjects were randomized to receive a placebo between the auscultatory measurements and the initiation of the ABPM at either visit 1 or visit 2. No medications or other interventions were performed between these measurements at the alternate visit. Subjects were informed they would be given a medication that may lower their BP. Neither the parents nor study team, however, were blinded to the fact that the pill was a placebo. Parents were instructed to answer any questions about the pill by saying it "may have an effect on BP." ABPM monitors were programmed to measure BP every 20 min between 7:00 am and 9:00 pm and every 30 min between 9:30 pm and 6:30 am. If a successful BP measurement was not obtained at a scheduled time, one additional measurement was attempted 3 min later. Measurements were performed with an 8-mm deflation bleed step. Automatic error control provided case-wise deletion of specific BP readings for a SBP of >240 or <70 mmHg, a DBP of >150 or <40 mmHg, a mean arterial pressure (MAP) of >200 mmHg or <40 mmHg, a pulse pressure of >150 mmHg or <20 mmHg, and a pulse rate of >200 or <20 bpm. Subjects were instructed to continue normal daily activities while wearing the ABPM monitor, excluding those which might damage the device, such as contact sports and swimming. Daytime and sleep periods were determined by patient diary entry. ABPM studies were considered adequate for analysis if the subject wore the monitor for at least 20 h, obtained at least 60 % of expected readings, and had at least one reading during every clock hour the monitor was worn [17] .
Statistical analysis
Demographic data was summarized for the population. SBP and DBP were calculated for 24-h, day, and night periods, and subjects were considered to be hypertensive if mean 24-h SBP or DBP was ≥95th percentile for height and gender [18] . Differences between groups were determined using paired t tests and McNemar's test, with a p<0.05 considered to be significant. All analysis was performed with SPSS ver. 19 (SPSS, Chicago, IL) and SAS ver. 9.2 (SAS Institute, Cary, NC).
Results
A total of 202 children were screened for the study, of whom 97 were ultimately included in the final analysis (See Fig. 1 ). Approximately 23 % of the population who completed the study failed to obtain adequate ABPM measurements at one or both visits, with only 86 subjects completing both ABPM readings successfully. Baseline demographics and screening BPs of included subjects are shown in Table 1 . Baseline demographics and auscultatory BP values did not differ between those included and those excluded from the analysis.
Overall mean 24-h, day, and night SBP and DBP were similar between visits (See Fig. 2 ). The diagnosis of HTN based on mean 24-h SBP or DBP was also similar between visits. One-quarter of the population had systolic HTN (26.09 % with placebo; 23.91 % without placebo; p00.62) and one-tenth had diastolic HTN (DBP 9.78 % with Fig. 1 Study enrollment. *Some subjects met more than one exclusion criteria. †Other reasons for exclusion included heart rate <2nd or >98th percentile for age (n03), significant arrhythmia (n01), height out of range for published pediatric blood pressure (BP) normal values (n07), and taking anti-hypertensive medications at the time of screening (n01). ABPM Ambulatory blood pressure monitoring placebo; 10.87 % without placebo; p00.71). Having a diagnosis of HTN either by mean entry casual BP or ABPM measures obtained without placebo did not change the impact of placebo on mean BP levels (See Table 2 ). Similar stratified analyses by age group (8-12 years vs. 13-16 years) and obesity status found that neither influenced the impact of placebo on mean BP levels.
Discussion
The results of this study demonstrate that placebo had no impact on the mean 24-h, day, and night BP measured by ABPM in a group of children and adolescents with elevated BP. This lack of placebo effect was also observed in children with confirmed HTN. These results are similar to observations in adults using ABPM devices [19] , but contrast the noted effect of placebo on casual (office) BP measurements in patients of all ages. The BP lowering effects of placebo on casual BP measurements have been demonstrated in multiple pediatric trials [9] . In fact, experience from one trial suggests that 17 % of "hypertensive" children will have a normal BP after 1 week of single-blind placebo therapy [13] . This compares to normalization rates as high as 30 % in adults [20] . The noted lack of placebo effect on ABPM measures in adults has led to its utilization as the primary BP measurement in several adult anti-hypertensive trials [21] [22] [23] . These trials compare anti-hypertensive agents without a placebo arm, which ensures that hypertensive adults may participate in clinical trials without the potentially negative effect of delaying therapy.
ABPM offers several advantages for future pediatric antihypertensive trials. Disqualifying subjects with white-coat HTN determined by ABPM may decrease the number of subjects necessary to prove drug efficacy [24] . ABPM will also identify BP lowering effects which do not persist for a full 24-h time period and provides an approach by which to better assess pharmacokinetic-pharmacodynamic relationships [25] . Finally, the majority of anti-hypertensive trials include patients with isolated mild to moderate HTN. Children with secondary hypertension, diabetes, known target organ damage, and severe HTN are traditionally excluded from these studies due to ethical concerns over delaying drug therapy. While children with severe HTN were also excluded from this study, ABPM may provide a tool for evaluating BP response in populations that have previously been excluded from anti-hypertensive trials due to concerns over the use of placebos.
There are a number of limitations to our current study. Only 79 % of the study cohort who completed the study satisfactorily completed the ABPM at both visits. While the procedure was well tolerated, this completion rate is lower than has been previously reported in pediatric studies [26, 27] . Future studies should include procedures for repeating ABPM studies that were deemed inadequate to prevent the loss of subjects due to incomplete data. In addition, casual BP measurements at visit 1 were used to determine subject eligibility, and the placebo pill was given after these measurements but prior to initiating the ABPM, resulting in an Fig. 2 Effect of placebo on mean BP by time period. SBP Systolic blood pressure, DBP diastolic blood pressure inability to evaluate the effect of placebo on casual BP measurements. Inclusion of this comparison in future studies will verify that the study population is in fact subject to the placebo effect described in the literature. Finally, the study reports findings based on the administration of only one placebo dose. While pharmacokinetic studies often utilize only one dose of medication, most studies evaluating the efficacy of an anti-hypertensive utilize placebo over an extended period of time. The extent to which the results of this study can be generalized to a longer exposure to placebo are unknown. Despite these limitations, the study represents the first to describe the effects of placebo on ABPM in children with HTN. In addition, the study population was diverse and obtained from multiple study sites, thus increasing the ability to generalize these findings to other populations. The multi-site design also demonstrated the ability to use this technology in multi-center studies of children similar to most pharmaceutical trials.
In conclusion, the results reported here provide evidence that ABPM represents an effective tool for measuring BP in pediatric anti-hypertensive trials and supports the potential elimination of the placebo arm in comparative dose studies of anti-hypertensive drugs in children. These studies could potentially include more children with high-risk profiles for hypertensive morbidity. Additional studies to confirm these findings and to refine protocols to ensure complete collection of ABPM data in this population are warranted. 
